In another article in this issue, Schelleman et al. (4) examine the cardiovascular safety of methylphenidate in adults. This is one of three articles assessing ADHD drugs and serious cardiovascular events released in rapid succession in three different medical journals; it joins an article by Cooper et al. published in the New England Journal of Medicine (5) and one by Schelleman et al. in Pediatrics (6). In their article in this issue, Schelleman and colleagues report on their analysis of a database that included 43,999 new methylphenidate users and 175,955 nonusers, all adults. While the authors found no statistically significant association of methylphenidate use with stroke, myocardial infarction, or a composite endpoint of stroke or myocardial infarction, they observed 1.8 times the risk of ventricular arrhythmia or sudden death and 1.7 times the risk of all-cause death among methylphenidate users compared with nonusers. The authors note, however, that the inverse association with dose observed in the study may argue against a causal association. In Pediatrics, Schelleman et al. reported that the rate of cardiovascular events in 241,417 children exposed to ADHD pharmacotherapy was low and in general no higher than in unexposed comparison children (6). The number of events was so low overall, however, that the ability to identify relative increases in rate is limited. The Cooper et al. study reported in the New England Journal of Medicine included 1,200,438 children and young adults 2–24 years of age, with 2,579,104 person-years of follow-up, which included 373,667 person-years of ADHD pharmacotherapy. The authors concluded that there was no increased risk for serious cardiovascular events for current users of ADHD medications.